Implantica launches RefluxStop in US after FDA approval
XLV•Implantica launched its RefluxStop implant in the US following FDA clearance, beginning its commercial rollout and entry into the US GERD surgery market.
1. US commercial launch
Implantica launched RefluxStop at the 2026 American Foregut Society meeting in Washington, D.C. The event drew more than 120 clinicians and led to nearly 30 follow-up meetings to support onboarding new sites. Management said it had shifted focus to systematic US expansion, targeting adoption by major medical centers.
